Bluejay Therapeutics is planning an IPO in the US, aiming to raise $150 million.

Bluejay Therapeutics, a pharmaceutical company specializing in severe viral and liver diseases, is reportedly planning an initial public offering (IPO) in the United States, according to Bloomberg News sources. The company may go public as early as next month, with JPMorgan Chase, Jefferies Financial Group, and Cantor Fitzgerald assisting in the process. The aim is to raise a minimum of $150 million through the offering.

Discussions are still ongoing, and details such as the size and timing of the IPO may change. Representatives from Bluejay, Cantor Fitzgerald, JPMorgan, and Jefferies have declined to comment on the matter. This article has been generated with the assistance of AI, translated, and reviewed by an editor. For more information, please refer to our Terms and Conditions section.